Hospira's Precedex Phase IV Trial Postponed To 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The post-marketing safety study is being revised with FDA input. The sedative Precedex makes up only a small portion of Hospira's specialty injectables sales, which totaled $235 mil. in the U.S. for the third quarter.